FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2607028219> ?p ?o ?g. }

• W2607028219 endingPage "1468" @default.
• W2607028219 startingPage "1458" @default.
• W2607028219 abstract "Bone metastases are a common cause of morbidity in patients with prostate carcinoma. We studied the effect of a new bisphosphonate, zoledronic acid, which blocks bone destruction, on skeletal complications in prostate cancer patients with bone metastases.Patients with hormone-refractory prostate cancer and a history of bone metastases were randomly assigned to a double-blind treatment regimen of intravenous zoledronic acid at 4 mg (N = 214), zoledronic acid at 8 mg (subsequently reduced to 4 mg; 8/4) (N = 221), or placebo (N = 208) every 3 weeks for 15 months. Proportions of patients with skeletal-related events, time to the first skeletal-related event, skeletal morbidity rate, pain and analgesic scores, disease progression, and safety were assessed. All statistical tests were two-sided.Approximately 38% of patients who received zoledronic acid at 4 mg, 28% who received zoledronic acid at 8/4 mg, and 31% who received placebo completed the study. A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222). Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo). Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001). Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid, but there were no differences in disease progression, performance status, or quality-of-life scores among the groups. Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated, but the 8-mg dose was associated with renal function deterioration.Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases." @default.
• W2607028219 created "2017-04-28" @default.
• W2607028219 creator A5005016975 @default.
• W2607028219 creator A5016199878 @default.
• W2607028219 creator A5036828612 @default.
• W2607028219 creator A5039005518 @default.
• W2607028219 creator A5046888497 @default.
• W2607028219 creator A5053457391 @default.
• W2607028219 creator A5053749991 @default.
• W2607028219 creator A5057439948 @default.
• W2607028219 creator A5078174436 @default.
• W2607028219 creator A5091685985 @default.
• W2607028219 date "2002-10-02" @default.
• W2607028219 modified "2023-10-10" @default.
• W2607028219 title "A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma" @default.
• W2607028219 cites W1513170608 @default.
• W2607028219 cites W1517801548 @default.
• W2607028219 cites W1966366668 @default.
• W2607028219 cites W1967168865 @default.
• W2607028219 cites W1970993628 @default.
• W2607028219 cites W1977543620 @default.
• W2607028219 cites W1991656070 @default.
• W2607028219 cites W1993701679 @default.
• W2607028219 cites W2022531799 @default.
• W2607028219 cites W2024266959 @default.
• W2607028219 cites W2026455376 @default.
• W2607028219 cites W2029838719 @default.
• W2607028219 cites W2035882770 @default.
• W2607028219 cites W2036488551 @default.
• W2607028219 cites W2044365993 @default.
• W2607028219 cites W2058681718 @default.
• W2607028219 cites W2066553392 @default.
• W2607028219 cites W2066845679 @default.
• W2607028219 cites W2077304538 @default.
• W2607028219 cites W2078899066 @default.
• W2607028219 cites W2086556166 @default.
• W2607028219 cites W2089514388 @default.
• W2607028219 cites W2093871127 @default.
• W2607028219 cites W2105258029 @default.
• W2607028219 cites W2114991203 @default.
• W2607028219 cites W2134661141 @default.
• W2607028219 cites W2135241080 @default.
• W2607028219 cites W2159622173 @default.
• W2607028219 cites W2316096113 @default.
• W2607028219 cites W2325302070 @default.
• W2607028219 cites W2403355975 @default.
• W2607028219 cites W2408935243 @default.
• W2607028219 cites W2415481317 @default.
• W2607028219 cites W2473786944 @default.
• W2607028219 cites W26375256 @default.
• W2607028219 cites W4206100111 @default.
• W2607028219 cites W4240322662 @default.
• W2607028219 doi "https://doi.org/10.1093/jnci/94.19.1458" @default.
• W2607028219 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12359855" @default.
• W2607028219 hasPublicationYear "2002" @default.
• W2607028219 type Work @default.
• W2607028219 sameAs 2607028219 @default.
• W2607028219 citedByCount "1530" @default.
• W2607028219 countsByYear W26070282192012 @default.
• W2607028219 countsByYear W26070282192013 @default.
• W2607028219 countsByYear W26070282192014 @default.
• W2607028219 countsByYear W26070282192015 @default.
• W2607028219 countsByYear W26070282192016 @default.
• W2607028219 countsByYear W26070282192017 @default.
• W2607028219 countsByYear W26070282192018 @default.
• W2607028219 countsByYear W26070282192019 @default.
• W2607028219 countsByYear W26070282192020 @default.
• W2607028219 countsByYear W26070282192021 @default.
• W2607028219 countsByYear W26070282192022 @default.
• W2607028219 countsByYear W26070282192023 @default.
• W2607028219 crossrefType "journal-article" @default.
• W2607028219 hasAuthorship W2607028219A5005016975 @default.
• W2607028219 hasAuthorship W2607028219A5016199878 @default.
• W2607028219 hasAuthorship W2607028219A5036828612 @default.
• W2607028219 hasAuthorship W2607028219A5039005518 @default.
• W2607028219 hasAuthorship W2607028219A5046888497 @default.
• W2607028219 hasAuthorship W2607028219A5053457391 @default.
• W2607028219 hasAuthorship W2607028219A5053749991 @default.
• W2607028219 hasAuthorship W2607028219A5057439948 @default.
• W2607028219 hasAuthorship W2607028219A5078174436 @default.
• W2607028219 hasAuthorship W2607028219A5091685985 @default.
• W2607028219 hasBestOaLocation W26070282191 @default.
• W2607028219 hasConcept C121608353 @default.
• W2607028219 hasConcept C126322002 @default.
• W2607028219 hasConcept C126894567 @default.
• W2607028219 hasConcept C141071460 @default.
• W2607028219 hasConcept C142724271 @default.
• W2607028219 hasConcept C204787440 @default.
• W2607028219 hasConcept C27081682 @default.
• W2607028219 hasConcept C2776326535 @default.
• W2607028219 hasConcept C2776541429 @default.
• W2607028219 hasConcept C2777251235 @default.
• W2607028219 hasConcept C2780192828 @default.
• W2607028219 hasConcept C71924100 @default.
• W2607028219 hasConceptScore W2607028219C121608353 @default.
• W2607028219 hasConceptScore W2607028219C126322002 @default.
• W2607028219 hasConceptScore W2607028219C126894567 @default.
• W2607028219 hasConceptScore W2607028219C141071460 @default.

• next